Stockscreener 앱 받기
55.56
1.76%
0.96
시간 외 거래:
55.50
-0.06
-0.11%
전일 마감가:
$54.60
열려 있는:
$54.56
하루 거래량:
11.35M
Relative Volume:
0.76
시가총액:
$113.11B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
18.76
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
+2.47%
1개월 성능:
+1.68%
6개월 성능:
+14.72%
1년 성능:
-8.32%
1일 변동 폭
$54.56
$56.12
1주일 범위
$53.55
$56.12
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.56 | 111.15B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,039.51 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
224.44 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.93 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
152.22 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.89 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Finviz
Bristol-Myers Squibb (BMY) Leads Record Lobbying Surge in Health - GuruFocus
Bristol-Myers Squibb Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) - Benzinga
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $60 - 富途牛牛
What the Options Market Tells Us About Bristol-Myers Squibb - Benzinga
Bristol Myers Squibb Company $BMY Shares Sold by Quilter Plc - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb: The Rerating Was FastThe Proof Will Be Slow (Rating Downgrade) - Seeking Alpha
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. - Finviz
Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments - Yahoo Finance UK
Bristol Myers Squibb and Janux Launch Partnership on Tumor-Activated T Cell Engagers - Oncodaily
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - Finviz
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Did AI Lung Imaging And New HCM Data Just Shift Bristol Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Nigeria
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Pharmaceutical Technology
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com South Africa
Is BMY's Deep Pipeline the Key to Its Next Growth Phase? - Yahoo Finance
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Janux, Bristol Myers Squibb partner on tumor-activated therapy - Investing.com
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration - Investing.com
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer - marketscreener.com
Bristol Myers taps Janux cancer tech in deal worth up to $800M - Stock Titan
Hepatitis Therapeutics Market Overview and Leading Players: - openPR.com
Bristol Myers Squibb teams up with Microsoft for AI-powered lung cancer detection - Mugglehead Magazine
Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal - Law360
Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery - Insider Monkey
15 Best High Yield Stocks To Buy - Insider Monkey
Syngene Extends Research Collaboration with Bristol Myers Squibb till 2035 - Chemical Industry Digest
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026 - Insider Monkey
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier By Investing.com - Investing.com South Africa
Bernstein Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock - Insider Monkey
Bristol Myers (BMY) Teams Up with Microsoft for Lung Cancer Dete - GuruFocus
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - Yahoo Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 - Yahoo Finance
Microsoft (MSFT) and Bristol Myers Squibb (BMY) Partner to Enhan - GuruFocus
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
Guggenheim Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62 - 富途资讯
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
1.70%
자본화:
|
볼륨(24시간):